SwePub
Sök i SwePub databas

  Utökad sökning

Träfflista för sökning "L773:1021 335X OR L773:1791 2431 "

Sökning: L773:1021 335X OR L773:1791 2431

Sortera/gruppera träfflistan
   
NumreringReferensOmslagsbildHitta
1.
  • Andersson, Ken G, et al. (författare)
  • Comparative evaluation of 111In-labeled NOTA‑conjugated affibody molecules for visualization of HER3 expression in malignant tumors
  • 2015
  • Ingår i: Oncology Reports. - Spandidos Publications. - 1021-335X .- 1791-2431. ; 34:2, s. 1042-8
  • Tidskriftsartikel (refereegranskat)abstract
    • <p>Expression of human epidermal growth factor receptor type 3 (HER3) in malignant tumors has been associated with resistance to a variety of anticancer therapies. Several anti-HER3 monoclonal antibodies are currently under pre-clinical and clinical development aiming to overcome HER3-mediated resistance. Radionuclide molecular imaging of HER3 expression may improve treatment by allowing the selection of suitable patients for HER3-targeted therapy. Affibody molecules are a class of small (7kDa) high-affinity targeting proteins with appreciable potential as molecular imaging probes. In a recent study, we selected affibody molecules with affinity to HER3 at a low picomolar range. The aim of the present study was to develop an anti-HER3 affibody molecule suitable for labeling with radiometals. The HEHEHE-Z08698-NOTA and HEHEHE-Z08699-NOTA HER3-specific affibody molecules were labeled with indium‑111 (111In) and assessed invitro and invivo for imaging properties using single photon emission computed tomography (SPECT). Labeling of HEHEHE-Z08698-NOTA and HEHEHE-Z08699-NOTA with 111In provided stable conjugates. Invitro cell tests demonstrated specific binding of the two conjugates to HER3-expressing BT‑474 breast carcinoma cells. In mice bearing BT‑474 xenografts, the tumor uptake of the two conjugates was receptor‑specific. Direct invivo comparison of 111In-HEHEHE-Z08698-NOTA and 111In-HEHEHE-Z08699‑NOTA demonstrated that the two conjugates provided equal radioactivity uptake in tumors, although the tumor-to-blood ratio was improved for 111In-HEHEHE-Z08698-NOTA [12±3 vs. 8±1, 4h post injection (p.i.)] due to more efficient blood clearance. 111In-HEHEHE-Z08698-NOTA is a promising candidate for imaging of HER3-expression in malignant tumors using SPECT. Results of the present study indicate that this conjugate could be used for patient stratification for anti-HER3 therapy.</p>
  •  
2.
  • Andersson, Ken G., et al. (författare)
  • Comparative evaluation of 111In-labeled NOTA‑conjugated affibody molecules for visualization of HER3 expression in malignant tumors
  • 2015
  • Ingår i: Oncology Reports. - 1021-335X .- 1791-2431. ; 34:2, s. 1042-1048
  • Tidskriftsartikel (refereegranskat)abstract
    • <p>Expression of human epidermal growth factor receptor type 3 (HER3) in malignant tumors has been associated with resistance to a variety of anticancer therapies. Several anti-HER3 monoclonal antibodies are currently under pre-clinical and clinical development aiming to overcome HER3-mediated resistance. Radionuclide molecular imaging of HER3 expression may improve treatment by allowing the selection of suitable patients for HER3-targeted therapy. Affibody molecules are a class of small (7 kDa) high-affinity targeting proteins with appreciable potential as molecular imaging probes. In a recent study, we selected affibody molecules with affinity to HER3 at a low picomolar range. The aim of the present study was to develop an anti-HER3 affibody molecule suitable for labeling with radiometals. The HEHEHE-Z08698-NOTA and HEHEHE-Z08699-NOTA HER3-specific affibody molecules were labeled with indium-111 (In-111) and assessed in vitro and in vivo for imaging properties using single photon emission computed tomography (SPECT). Labeling of HEHEHE-Z08698-NOTA and HEHEHE-Z08699-NOTA with In-111 provided stable conjugates. In vitro cell tests demonstrated specific binding of the two conjugates to HER3-expressing BT-474 breast carcinoma cells. In mice bearing BT-474 xenografts, the tumor uptake of the two conjugates was receptor-specific. Direct in vivo comparison of In-111-HEHEHE-Z08698-NOTA and In-111-HEHEHE-Z08699-NOTA demonstrated that the two conjugates provided equal radioactivity uptake in tumors, although the tumor-to-blood ratio was improved for In-111-HEHEHE-Z08698-NOTA [12 +/- 3 vs. 8 +/- 1,4 h post injection (p.i)] due to more efficient blood clearance. In-111-HEHEHE-Z08698-NOTA is a promising candidate for imaging of HER3-expression in malignant tumors using SPECT. Results of the present study indicate that this conjugate could be used for patient stratification for anti-HER3 therapy.</p>
  •  
3.
  • Argyropoulos, C., et al. (författare)
  • Operational criteria for selecting a cDNA microarray data normalization algorithm
  • 2006
  • Ingår i: Oncology Reports. - 1021-335X .- 1791-2431. ; 15:4, s. 983-996
  • Tidskriftsartikel (refereegranskat)abstract
    • <p>Microarray technology allows gene expression profiling at a global level. Many algorithms for the normalization of raw microarray data have been proposed, but no attempt has yet been made to propose operationally verifiable criteria for their comparative evaluation, which is necessary for the selection of the most appropriate method for a given dataset. This study develops a set of operational criteria for assessing the impact of various normalization algorithms in terms of accuracy (bias), precision (variance) and over-fitting (information reduction). The use of these criteria is illustrated by applying the three most widely used algorithms (global median normalization, spiked-in based normalization and lowess) on a specifically designed, multiply-controlled dataset.</p>
  •  
4.
  • Arlehag, L, et al. (författare)
  • ATM expression in rectal cancers with or without preoperative radiotherapy
  • 2005
  • Ingår i: Oncology Reports. - 1021-335X .- 1791-2431. ; 14:2, s. 313-317
  • Tidskriftsartikel (refereegranskat)abstract
    • <p>Patients with ATM (Ataxia-Telangiectasia mutated) mutation show increased sensitivity to radiation and have a higher risk of developing malignancies. The present study aimed to investigate whether ATM expression was related to radiotherapy, and clinicopathological and biological variables in rectal cancers. ATM expression was immunohistochemically examined in 78 rectal cancers from patients who participated in a Swedish rectal cancer trial of preoperative radiotherapy. Of 78 patients, 44 underwent surgery alone, and 34 underwent both preoperative radiotherapy and surgery. Fifty-eight cases had normal rectal mucosa adjacent to the tumour. The results showed that, compared to normal mucosa, tumours had less nuclear (p=0.03) but more cytoplasmic expression of ATM (p=0.004). In tumours, less expression of ATM, either in the nucleus (p=0.07) or in the cytoplasm (p=0.02 for staining intensity, and p=0.07 for staining percentage), tended to be correlated with male patients. Also, ATM expression was not related to radiotherapy or other clinicopathological and biological variables (p &gt; 0.05). In conclusion, the pattern of ATM expression was changed from normal mucosa to tumour. Less expression of ATM may be related to males.</p>
  •  
5.
  • Armakolas, Athanasios, et al. (författare)
  • Subdivision of molecularly-classified groups by new gene signatures in breast cancer patients
  • 2012
  • Ingår i: Oncology Reports. - 1021-335X .- 1791-2431. ; 28:6, s. 2255-2263
  • Tidskriftsartikel (refereegranskat)abstract
    • <p>Gene expression patterns as well as gene interactions are under investigation for their involvement in tumour heterogeneity. The molecular classification of breast cancer based on hormone receptor expression, grade and HER2 receptor levels, is indicative but not adequate enough to complete the prognostic data. The objectives of this study were to validate the prognostic value of 19 genes, solely, and as parts of classifiers (sets of genes), in breast cancer patients and to determine whether the expression of these genes and classifiers is correlated with breast cancer molecular classification. Gene expression was examined in the blood of 88 breast cancer patients and 50 healthy controls using multiplex quantitative real-time PCR. Patients with a second primary malignancy showed a statistically significant difference when compared with: i) patients with a single breast cancer, for an 8-gene classifier (p&lt;0.02); and ii) healthy individuals (classifier FBX033, FLJ339115) (p&lt;0.01), with respect to gene expression. The classifier ENY2, USP38 was associated with the development of primary breast cancer. A newly established classifier (ENY2, USP38, RPS7, Osbpl-1 and ETF1) indicated a statistically significant association with HER2 subtype patients, compared to patients with a different molecular classification (p&lt;0.04). The gene FLJ33915 was differentially expressed in a subgroup of HER2-positive patients with infiltrated axillary lymph nodes (p&lt;0.028). We validated the prognostic value of 4 classifiers for primary and second primary malignancy. Evidence of a classifier predicting the HER2 subtype and the gene FLJ33915 which subdivides HER2 subtype patients is also presented.</p>
  •  
6.
  • Babaei, Mohammad Hossein, et al. (författare)
  • [99mTc] HYNIC-hEGF, a potential agent for imaging of EGF receptors in vivo : preparation and pre-clinical evaluation
  • 2005
  • Ingår i: Oncology Reports. - 1021-335X .- 1791-2431. ; 13:6, s. 1169-75
  • Tidskriftsartikel (refereegranskat)abstract
    • <p>Expression of epidermal growth factor receptors (EGFR) has prognostic and predictive value in many kinds of tumors. Imaging of expression of EGFR in vivo may give valuable diagnostic information. The epidermal growth factor (EGF), a natural ligand, is a possible candidate for the targeting of EGFR. The present study describes a method for preparation of (99m)Tc-EGF via the hydrazinopyridine-3-carboxylic acid (HYNIC) conjugation using tricine and ethylenediamine-N,N'-diacetic acid (EDDA) as co-ligands. Both conjugates bound EGFR expressing cells with nanomolar affinity, and demonstrated good intracellular retention. The complex with EDDA demonstrated much higher stability in blood serum and during cysteine challenge. Biodistribution of (99m)Tc-EDDA-HYNIC-EGF in normal mice demonstrated fast blood clearance of conjugate, and its ability to bind EGFR in vivo. (99m)Tc-EDDA-HYNIC-EGF is a promising candidate for visualization of EGFR expression in vivo.</p>
  •  
7.
  • Berglund, Mattias, et al. (författare)
  • High expression of microRNA-200c predicts poor clinical outcome in diffuse large B-cell lymphoma
  • 2013
  • Ingår i: Oncology Reports. - 1021-335X .- 1791-2431. ; 29:2, s. 720-724
  • Tidskriftsartikel (refereegranskat)abstract
    • <p>Diffuse large B-cell lymphoma (DLBCL) is a heterogeneous group of B-cell lymphomas. A new and important tool for understanding the biology and clinical course of DLBCL is microRNA expression. This study presents microRNA-200c expression data from 61 DLBCL patients treated with CHOP or R-CHOP. Patients with high microRNA-200c expression had a median survival of 20.3 months and a significantly shorter overall survival (P=0.019) compared to patients with low microRNA-200c expression, who had a median survival of 35.8 months. We also found that patients treated with R-CHOP only and displaying high microRNA-200c expression had a significantly shorter overall survival compared to patients with low microRNA-200c expression, where all patients were still alive at the time of the last follow-up (P=0.0036). Lastly, we found that patients with high microRNA-200c expression had a significantly shorter time from initial diagnosis to the first relapse compared to patients with low microRNA-200c expression (P=0.0001). To our knowledge, this is the first study showing that the expression of microRNA-200c affects the clinical outcome of DLBCL patients, and that microRNA-200c is involved in the biology of DLBCL development, although larger studies are necessary to confirm this. Further investigations may also help to elucidate the biological role of microRNA-200c in DLBCL.</p>
  •  
8.
  • Bu, H, et al. (författare)
  • Significance of glutathione S-transferases M1, T1 and P1 polymorphisms in Swedish melanoma patients.
  • 2007
  • Ingår i: Oncology Reports. - 1021-335X .- 1791-2431. ; 17:4, s. 859-864
  • Tidskriftsartikel (refereegranskat)abstract
    • <p>Polymorphisms of GSTM1, GSTT1 and GSTP1 were examined in melanoma patients and tumor-free individuals. Relationships between the polymorphisms and tumor characteristics and pigment phenotypes of the patients were analyzed. There was no significant difference in GSTM1 null and GSTT1 null genotypes nor GSTP1 GG genotype between melanoma patients and controls. In melanoma patients, these polymorphisms were not correlated with early or later onset of melanomas or gender of the patients. Frequency of GSTM1 null genotype was higher in patients with melanoma >2.5 mm than in those with tumors <1.0 mm, and higher frequency was found in nodular melanoma than in the other tumor types. GSTP1 GG genotype was more often found in the patients with brown and mixed eye color or brown and black hair than those with blue and green eyes or blond hair. It is unlikely that polymorphisms of GSTM1, GSTT1 and GSTP1 are general risk factors for melanoma in the Swedish population. GSTM1 null genotype was correlated with Breslow thickness and tumor type, which might serve as an additional biomarker for a rapid tumor progression. GSTP1 GG increases risk for melanoma in the subgroup of individuals with dark eyes or hair.</p>
  •  
9.
  • Byström, P., et al. (författare)
  • An explorative study on the clinical utility of baseline and serial serum tumour marker measurements in advanced upper gastrointestinal cancer
  • 2010
  • Ingår i: Oncology Reports. - 1021-335X .- 1791-2431. ; 24:6, s. 1645-1652
  • Tidskriftsartikel (refereegranskat)abstract
    • <p>The value of early tumour marker changes during palliative chemotherapy in patients with upper gastrointestinal adenocarcinoma (UGIA) is unclear. Seventy-three patients with advanced UGIA were randomised to receive 45 mg/m2 docetaxel or 180 mg/m2 irinotecan with 5-FU/leucovorin. After every 2nd course the patients were crossed over to the other regimen. Serum was sampled before start of chemotherapy and every 2nd week during 8 weeks for CEA, TPA, TPS, CA72-4, CA19-9 and CA242 measurements. Eighteen patients (25%) had partial response (PR) and 21 patients had stable disease for at least 4 months (SD4). All baseline marker levels, except CA72-4, correlated with time to progression and survival. Patients with normal levels, except CA72-4, also had more clinical responses (PR+SD4) than patients with elevated values. Tumour marker changes early during treatment provided modest predictive information for tumour response and survival. A model combining baseline level, the change and the interaction between them gave the best prediction of outcome, however, insignificantly better than baseline level for all markers except CA242. Baseline tumour marker levels provide prognostic information for patients with UGIA on palliative chemotherapy. Early changes generally failed to provide accurate information for tumour response and survival.</p>
  •  
10.
  • Campa, Daniele, et al. (författare)
  • Genetic variability of the forkhead box O3 and prostate cancer risk in the European Prospective Investigation on Cancer
  • 2011
  • Ingår i: Oncology Reports. - Athen : National Hellenic Research Foundation. - 1021-335X .- 1791-2431. ; 26:4, s. 979-986
  • Tidskriftsartikel (refereegranskat)abstract
    • <p>Forkhead box O3 (FOXO3) has a wide range of functions: it promotes tumor suppression, cell cycle arrest, repair of damaged DNA, detoxification of reactive oxygen species, apoptosis and plays a pivotal role in promoting longevity. FOXO3 is a key downstream target of the PI3K-Akt pathway in response to cellular stimulation by growth factors or insulin and has been proposed as a bridge between ageing and tumor suppression. Three SNPs in the FOXO3 gene (rs3800231, rs9400239 and rs479744) that have been shown to be strongly and consistently associated with longevity, were examined in relation to PC risk in a case control study of 1571 incident PC cases and 1840 controls nested within the European Prospective Investigation into Cancer and Nutrition (EPIC). There was no statistically significant association between the SNPs and PC risk regardless of the model of inheritance (dominant, codominant and recessive). The associations were not modified by disease aggressiveness, circulating levels of steroid sex hormones, or IGFs or BMI. We conclude that polymorphisms in the FOXO3 gene that are associated with longevity are not major risk factors for PC risk, in this population of Caucasian men.</p>
  •  
Skapa referenser, mejla, bekava och länka
Åtkomst
fritt online (11)
Typ av publikation
tidskriftsartikel (147)
Typ av innehåll
refereegranskat (147)
övrigt vetenskapligt (1)
Författare/redaktör
Tolmachev, Vladimir, (9)
Mertens, Fredrik, (7)
Orlova, Anna, (7)
Glimelius, Bengt, (6)
Sun, Xiao-Feng, 1959 ... (6)
Andersson, S (6)
visa fler...
Wågsäter, Dick, (6)
Zhang, Hong, 1957-, (5)
Glimelius, B, (4)
Lindblom, Annika (4)
Lennernäs, Bo, 1963- ... (4)
Lundqvist, Hans (3)
Nilsson, S (3)
Eriksson, M, (3)
Ståhl, Stefan, (3)
Skoog, L, (3)
Stål, Olle, (2)
Nilsson, Per J. (2)
Kaaks, Rudolf (2)
Hjerpe, A, (2)
Johansson, B (2)
Nilsson, Torbjörn K (2)
Eriksson, Mikael, (2)
Jansson, Agneta, 197 ... (2)
Farnebo, Lovisa, (2)
Stahl, S (2)
Linder, S, (2)
Nygren, Peter, (2)
Fornander, T, (2)
Stal, O (2)
Fornander, Tommy, (2)
Gedda, Lars, (2)
Sandström, Mattias, (2)
Tidefelt, Ulf, (2)
Nordenskjold, B (2)
Nordenskjöld, Bo, (2)
Hardell, Lennart (2)
Heegaard, S (2)
Schedvins, K (2)
Marquez, M, (2)
Holmberg, AR (2)
Albertsson, Per, 196 ... (2)
Palmqvist, Richard, (2)
Nilbert, Mef, (2)
Borg, Åke, (2)
Paul, Christer, (2)
Rosell, Johan, (2)
Löfblom, John, (2)
Sandström, Per, (2)
Almqvist, Ylva, (2)
visa färre...
Lärosäte
Karolinska Institutet (42)
Linköpings universitet (30)
Uppsala universitet (21)
Lunds universitet (18)
Göteborgs universitet (13)
Örebro universitet (11)
visa fler...
Umeå universitet (9)
Kungliga Tekniska Högskolan (3)
Högskolan i Jönköping (3)
Högskolan i Skövde (3)
visa färre...
Språk
Engelska (147)
Forskningsämne (UKÄ/SCB)
Medicin och hälsovetenskap (94)
Naturvetenskap (6)
Teknik (1)
Samhällsvetenskap (1)

År

 
pil uppåt Stäng

Kopiera och spara länken för att återkomma till aktuell vy